Cargando…

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation

Detalles Bibliográficos
Autores principales:	Vandyke, K, Fitter, S, Zannettino, A C W
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255273/ https://www.ncbi.nlm.nih.gov/pubmed/22829108 http://dx.doi.org/10.1038/bcj.2011.1

Ejemplares similares

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
por: Okabe, Seiichi, et al.
Publicado: (2011)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Bcr-Abl tyrosine kinase inhibitors- current status
por: Mughal, Anum, et al.
Publicado: (2013)

Acquired Resistance Mechanism for MET Tyrosine Kinase Inhibitor
por: Fujino, Toshio, et al.
Publicado: (2021)

Pulsatile high-dose treatment with antiangiogenic tyrosine kinase inhibitors improves clinical antitumor activity
por: Rovithi, Maria, et al.
Publicado: (2017)

Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Yun, Hwan-Jung, et al.
Publicado: (2015)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
por: Hennigs, Jan K, et al.
Publicado: (2011)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
por: Rodríguez-Agustín, Andrea, et al.
Publicado: (2023)

The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era
por: Kockerols, Camille C.B., et al.
Publicado: (2022)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
por: Saladi, Venkata Narasayya, et al.
Publicado: (2022)

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice
por: Gu, Yue, et al.
Publicado: (2023)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
por: Benner, Brooke, et al.
Publicado: (2021)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Atypical posterior reversible encephalopathy syndrome secondary to dasatinib
por: Nayak, Amiya Ranjan, et al.
Publicado: (2023)

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
por: Chang, Q, et al.
Publicado: (2008)

Dasatinib enhances anti-leukemia efficacy of chimeric antigen receptor T cells by inhibiting cell differentiation and exhaustion
por: Zhang, Hao, et al.
Publicado: (2021)

The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells
por: Borriello, Adriana, et al.
Publicado: (2011)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
por: Xiao, Xinhua, et al.
Publicado: (2020)

Pilose antler polypeptides promote chondrocyte proliferation via the tyrosine kinase signaling pathway
por: Lin, Jian-Hua, et al.
Publicado: (2011)

Compartmentalisation of EGFR signalling might potentiate the optimal use of EGFR tyrosine kinase inhibitors in cancer therapeutics
por: Karamouzis, M V, et al.
Publicado: (2007)

Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Schöffski, P, et al.
Publicado: (2010)

Successful Treatment of Rituximab-Refractory Waldenstrom Macroglobulinemia-Related Kidney Damage With Bruton Tyrosine Kinase Inhibitor
por: Nie, Guangyan, et al.
Publicado: (2021)

Low-dose tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study in China
por: Chen, Yilin, et al.
Publicado: (2022)

NDEL1-PDGFRB fusion gene in a myeloid malignancy with eosinophilia associated with resistance to tyrosine kinase inhibitors
por: Byrgazov, K, et al.
Publicado: (2017)

Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials
por: le Coutre, P D, et al.
Publicado: (2016)

Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
por: Barbarin, Alice, et al.
Publicado: (2020)

Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors
por: Novello, S, et al.
Publicado: (2010)

Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review
por: Din, Mohammad Ammad Ud, et al.
Publicado: (2022)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?
por: Roviello, Giandomenico, et al.
Publicado: (2021)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL
por: Laukkanen, S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_sljh61tti5ve2bi3nmh0vb3il3